Compare · GLP-1 agonist
Retatrutide vs Survodutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Retatrutide | Survodutide | |
|---|---|---|
| Evidence | 7/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. | An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data. |
| Full profile → | Full profile → |
Retatrutide
Retatrutide (Lilly's lab code LY3437943) is an experimental injectable drug being studied for obesity and type 2 diabetes. It has shown some of the biggest weight-loss numbers seen in any trial so far. But as of June 2026 it is not approved anywhere, and the big Phase 3 results that matter most…
Survodutide
Survodutide (its lab code is BI 456906) is an experimental injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has more real human research behind it than most peptides sold online, including several carefully run trials that compared it against a placebo (a…